Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2020-02-14 2:52 pm Purchase | 13G | CORVUS PHARMACEUTICALS INC CRVS | BIOTECHNOLOGY VALUE FUND L P | 3,082,997 9.9% | 50,147 (+1.65%) | View |
2020-02-14 2:52 pm Purchase | 13G | CIDARA THERAPEUTICS INC CDTX | BIOTECHNOLOGY VALUE FUND L P | 3,368,758 9.99% | 464,074 (+15.98%) | View |
2020-02-14 2:48 pm Sale | 13G | ALPINE IMMUNE SCIENCES INC ALPN | BIOTECHNOLOGY VALUE FUND L P | 1,137,764 6.1% | -63,954 (-5.32%) | View |
2020-02-14 2:44 pm Purchase | 13G | CALITHERA BIOSCIENCES INC CALA | BIOTECHNOLOGY VALUE FUND L P | 9,559,642 15.1% | 2,809,160 (+41.61%) | View |
2020-02-14 2:44 pm Sale | 13G | IDEAYA BIOSCIENCES INC IDYA | BIOTECHNOLOGY VALUE FUND L P | 1,436,429 7.1% | -69,000 (-4.58%) | View |
2020-02-14 2:41 pm Sale | 13G | MERSANA THERAPEUTICS INC MRSN | BIOTECHNOLOGY VALUE FUND L P | 3,755,553 7.4% | -1,170,866 (-23.77%) | View |
2020-02-14 2:39 pm Purchase | 13G | ESSA PHARMA INC EPIX | BIOTECHNOLOGY VALUE FUND L P | 2,640,565 12.7% | 1,310,865 (+98.58%) | View |
2020-02-14 2:39 pm Purchase | 13G | REPLIMUNE GROUP INC REPL | BIOTECHNOLOGY VALUE FUND L P | 2,309,109 6.5% | 702,292 (+43.71%) | View |
2020-02-14 2:37 pm Sale | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | BIOTECHNOLOGY VALUE FUND L P | 2,332,630 8.1% | -169,760 (-6.78%) | View |
2020-02-14 2:35 pm Purchase | 13G | MEI PHARMA INC MEIP | BIOTECHNOLOGY VALUE FUND L P | 6,886,425 6.4% | 2,367,564 (+52.39%) | View |
2020-02-14 2:33 pm Sale | 13G | KURA ONCOLOGY INC KURA | BIOTECHNOLOGY VALUE FUND L P | 1,998,276 4.4% | -776,880 (-27.99%) | View |
2020-02-14 2:29 pm Purchase | 13G | OVID THERAPEUTICS INC OVID | BIOTECHNOLOGY VALUE FUND L P | 5,255,301 9.99% | 1,483,301 (+39.32%) | View |
2020-02-13 5:30 pm Purchase | 13D | XOMA CORP COM XOMA | BIOTECHNOLOGY VALUE FUND L P | 3,895,177 35.4% | 1,252,772 (+47.41%) | View |
2020-02-10 2:49 pm Purchase | 13G | KEZAR LIFE SCIENCES INC KZR | BIOTECHNOLOGY VALUE FUND L P | 2,039,788 5.8% | 2,039,788 (New Position) | View |
2020-02-04 5:22 pm Sale | 13D | CTI BIOPHARMA CORP CTIC | BIOTECHNOLOGY VALUE FUND L P | 12,753,690 19.99% | -206 (-0.00%) | View |
2020-02-03 9:31 pm Purchase | 13G | ANAPTYSBIO INC ANAB | BIOTECHNOLOGY VALUE FUND L P | 1,441,565 5.3% | 847,168 (+142.53%) | View |
2020-01-10 5:22 pm Purchase | 13D | INFINITY PHARMACEUTICALS INC C INFI | BIOTECHNOLOGY VALUE FUND L P | 17,426,968 30.6% | 275,000 (+1.60%) | View |
2020-01-06 10:00 pm Purchase | 13G | CARTESIAN THERAPEUTICS, INC. C RNAC | BIOTECHNOLOGY VALUE FUND L P | 4,926,108 5.6% | 4,926,108 (New Position) | View |
2019-12-26 5:56 pm Purchase | 13D | FIVE PRIME THERAPEUTICS INC FPRX | BIOTECHNOLOGY VALUE FUND L P | 7,783,001 21.4% | 1,815,882 (+30.43%) | View |
2019-12-20 7:24 pm Purchase | 13D | XOMA CORP COM XOMA | BIOTECHNOLOGY VALUE FUND L P | 2,642,405 27.1% | 873,376 (+49.37%) | View |